Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

Simcere

More Like This

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Sobi to present new data at ASH 2023 Annual Meeting